Genzyme

Henri Termeer Dies

Henri Termeer, the former long-time head of Genzyme and "founder of the modern biotech industry," has died, the Boston Globe reports.

The firm also disclosed that it has paid $1.2 million in severance and bonuses related to its acquisition of Allegro Diagnostics.

The deal does not cover Voyager's fledgling effort to use RNAi to treat amyotrophic lateral sclerosis.

NEW YORK (GenomeWeb) – LabCorp subsidiary Esoterix Genetic Laboratories is suing Qiagen in a US district court alleging that Qiagen breached a licensing agreement between the companies regarding EGFR genetic testing by offering it for commercial research and diagnostic purposes ahead of US Food a

NEW YORK (GenomeWeb) – Researchers from Genzyme this month reported new proof-of-concept data showing that an expressed RNAi approach could be used to both prevent and treat the manifestations of Huntington's disease (HD) in an animal model of the condition.

Alnylam Pharmaceuticals announced this week that its partner Genzyme has exercised an option to buy 344,448 unregistered shares of Alnylam stock for $23 million as part of the companies broad genetic diseases alliance disclosed earlier this year.

On the heels of its acquisition of Merck's RNAi drug assets, Alnylam Pharmaceuticals this week announced that it has signed a deal giving partner Genzyme the rights to its existing and future genetic medicines programs in all territories outside of North America and Western Europ

NEW YORK (GenomeWeb News) – Genzyme and the National Organization for Rare Disorders (NORD) this week announced the creation of a fund to help patients with mysterious, undiagnosed illnesses.

Alnylam Pharmaceuticals last month announced that it has received a $7 million milestone payment from Genzyme based upon its positive data from a phase II trial of the TTR-mediated amyloidosis treatment patisiran, formerly known as ALN-TTR02.

Isis Pharmaceuticals and partner Genzyme announced this week that the US Food and Drug Administration has approved their antisense drug Kynamro, known generically as mipomersen, for the treatment of homozygous familial hypercholesterolemia.

Pages

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.